How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,911 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

341. Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. (Abstract)

Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. HIV-1 genetic diversity increases over the course of infection, and can be used to infer time since infection (TSI) and consequently also infection recency, crucial quantities for HIV-1 surveillance and the understanding of viral pathogenesis.We considered 313 HIV-infected individuals for whom reliable estimates of infection dates and next-generation

2019 Journal of Infectious Diseases

342. A Surveillance Data-Based Model System for Assessing the Effects of HIV Intervention and Prevention Strategies. (Abstract)

with HIV infection and persons at risk of acquiring HIV infection.HIV incidence, HIV prevalence, proportion of persons infected with HIV whose infection is diagnosed, and proportion of persons with diagnosed HIV infection who are virally suppressed.A model system based on the basic year-to-year algebraic relationships among the model variables and relying almost exclusively on HIV surveillance data was developed to project the course of HIV disease over a specified time period. Based on the most recent (...) A Surveillance Data-Based Model System for Assessing the Effects of HIV Intervention and Prevention Strategies. Build a dynamic model system to assess the effects of HIV intervention and prevention strategies on future annual numbers of new HIV infections, newly diagnosed cases of HIV infection, and deaths among persons infected with HIV.Model parameters are defined to quantify the putative effects of HIV prevention strategies that would increase HIV testing, thereby diagnosing infection

2019 Journal of Public Health Management and Practice

343. Topical treatments for HIV-related oral ulcers. (Abstract)

Topical treatments for HIV-related oral ulcers. In HIV-infected adults, oral ulcers occur more frequently, last longer and produce more painful symptoms than in immunocompetent people. Oral aphthous ulcers observed during the course of HIV infection may be severe and can result in significant morbidity in these patients. Such manifestations may interfere with oral functions and alter patients' quality of life.To evaluate the efficacy and side effects of topical agents used in the treatment (...) of HIV-related oral aphthous ulcers in adults.The following electronic databases were searched from the year 1980 to May 2011 for randomised controlled trials involving managements of oral ulcers, apthouses in HIV infected adults: EMBASE, PUBMED, the Cochrane Central Register of Controlled Trials (CENTRAL).Only randomised controlled trials that evaluated the efficacy of any topical agent in treating HIV oral aphthous ulcerations in HIV positive adults were considered.Two authors independently

2012 Cochrane

344. Recipient Assessment for Transplantation - HIV, HBV and HCV infection

Recipient Assessment for Transplantation - HIV, HBV and HCV infection ________________________________________________________________________________________________________________________ Recipient Assessment for Transplantation March 2013 Page 1 of 23 HIV, HBV and HCV infection Date written: November 2011 Author: David Gracey GUIDELINES a. Human immunodeficiency virus (HIV) We recommend that HIV infection should not preclude a patient from being assessed for kidney transplantation (Level 1D (...) immunodeficiency virus on maintenance hemodialysis. Kidney International, 1988. 34(2): p. 248-253. 16. ANZDATA, 2010 Annual Report. 2010, ANZDATA. 17. Abbott, K.C., et al., Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. Journal of the American Society of Nephrology, 2004. 15(6): p. 1633-9. 18. Roland, M.E. and P.G. Stock, Review of solid-organ transplantation in HIV-infected patients. Transplantation, 2003. 75(4

2013 KHA-CARI Guidelines

345. Intersectionality in HIV and Other Health-Related Research

Intersectionality in HIV and Other Health-Related Research Rapid Review #68: June 2013 Intersectionality in HIV and Other Health- Related Research Question What is the current knowledge/evidence on intersectionality in HIV and other health-related research? Key Take-Home Messages ? Human experiences cannot be reduced to singular characteristics as these characteristics interact with others to produce health outcomes. ? Using social categories, such as class, race, gender, sexual orientation (...) -research, and faced “interlocking barriers (e.g. HIV- related stigma, heteronormative assumptions and discriminatory treatment) that reduced access to HIV care and support.” Thus, “intersectional interventions are required to reduce the marginalization of LBQT women,” and “they should operate across micro, meso and macro levels of change.” Other health-related research Warner and Brown [24] used an intersectionality approach, grounded in life course theory, to explore differences in the trajectories

2013 Ontario HIV Treatment Network

346. Mindfulness-based Therapy for people living with HIV

in people living with HIV. A recent RCT with 76 participants compared MBSR to participants on a wait list and found reduced frequency, severity and distress from symptoms resulting from anti-retroviral therapy (ARTs).(3) In addition, two small studies (one a RCT and one a pilot study) found that HIV positive participants receiving MBSR (2) or practicing mindfulness meditation (4) over the course of 8 weeks stabilized or increased their CD4 counts. Participants in the pilot study reported that group (...) Mindfulness-based Therapy for people living with HIV Rapid Review #56: May 2012 Mindfulness-based therapy for people living with HIV Question What is the use and benefit of mindfulness-based interventions for people living with HIV/AIDS? Key Take-Home Messages ? Findings from five systematic reviews evaluating mindfulness-based interventions (MBIs) -- specifically mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) – have found beneficial effects on mental

2012 Ontario HIV Treatment Network

347. Population HIV transmission risk for serodiscordant couples in Guangxi, Southern China: A cohort study. Full Text available with Trip Pro

Population HIV transmission risk for serodiscordant couples in Guangxi, Southern China: A cohort study. We evaluated the risk of human immunodeficiency virus (HIV) transmission among serodiscordant couples with low adherence to antiretroviral therapy (ART).Data of heterosexual couples/partners in 2010 were extracted from an Internet-based system. Participants were then followed over the course of a year with 6- and 12-month assessments. Prevalence and density of HIV seroconversion were (...) calculated for spouses/partners who did not have a positive HIV test results at baseline. We calculated the transmission odds ratio (OR) value stratified by personal characteristics and behavioral correlates at 6- and 12-month follow-up, as well as seroconversion in spouses/partners over the year.A total of 5544 HIV/AIDS patients and their spouses/partners were recruited in this cohort. Incidence of HIV seroconversion among HIV-negative spouse/partner was 63.7/100 person years (PYs) (430/674.9) at the 6

2018 Medicine

348. Retrospective analysis of risk factors and gaps in prevention strategies for mother-to-child HIV transmission in Rio de Janeiro, Brazil. Full Text available with Trip Pro

likely than controls to continue receiving care throughout the cascade (p < 0.05). Motives for incompletion of PMTCT measures included infrastructural issues, such as HIV test results not being returned, but were most often due to lack of care-seeking. Over the course of the study period, PMTCT completion improved, although it remained below the 95% target for antenatal care, HIV testing, and antenatal ART set by the WHO. Adding concern, evaluation of co-infections indicated that case infants were (...) Retrospective analysis of risk factors and gaps in prevention strategies for mother-to-child HIV transmission in Rio de Janeiro, Brazil. Despite great progress made in methods to prevent mother-to-child transmission of HIV (MTCT), delivery and uptake of these measures remains a challenge in many countries. Although the Brazilian Ministry of Health aimed to eliminate MTCT by 2015, infection still occured in 15-24% of infants born to HIV-infected mothers. We sought to identify remaining factors

2018 BMC Public Health

349. Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in <i>falciparum</i>-negative HIV-infected Malawian adults stabilized on antiretrov Full Text available with Trip Pro

from 0 h to 14 days (AUC0-14 days) of lumefantrine and the safety profile of artemether-lumefantrine in malaria-negative human immunodeficiency virus (HIV)-infected adults in two steps. In step 1, a half-dose adult course of artemether-lumefantrine was administered as a safety check in four groups (n = 6/group): (i) antiretroviral naive, (ii) nevirapine-based ART, (iii) efavirenz-based ART, and (iv) ritonavir-boosted lopinavir-based ART. In step 2, a standard-dose adult course of artemether (...) Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretrov There is conflicting evidence of the impact of commonly used antiretroviral therapies (ARTs) on the pharmacokinetics of lumefantrine and the safety profile of artemether-lumefantrine. We compared the area under the concentration-time curve

2018 Antimicrobial Agents and Chemotherapy

350. Adapting an Evidence-based Intervention for Stigma-related Stress, Mental Health, and HIV Risk for MSM of Color in Small Urban Areas

once per week over the course of four months. The group will be "closed," in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members. Active Comparator: HIV Negative MSM 15 HIV- MSM will take part in 12 group sessions. Behavioral: ESTEEM conneCT Thirty participants will be assigned to one of two groups according to their HIV status. Twelve group sessions will take place at regular times once per week over the course (...) Adapting an Evidence-based Intervention for Stigma-related Stress, Mental Health, and HIV Risk for MSM of Color in Small Urban Areas Adapting an Evidence-based Intervention for Stigma-related Stress, Mental Health, and HIV Risk for MSM of Color in Small Urban Areas - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2018 Clinical Trials

351. Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV

of a 28-day course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood exposure to HIV. At baseline, participants are prescribed TAF/FTC/RPV and a blood test. At W6, all participants are contacted by phone to evaluate completeness and tolerability of the TAF/FTC/RPV regimen. Condition or disease Intervention/treatment Hiv Other: Non Interventional Study Detailed Description: At baseline, participants seek care in one of the centers of " Pays de la Loire " area after (...) Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2018 Clinical Trials

352. Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine in HIV and Transplant Patients

vaccination. This study will provide a comparison of immunogenicity of Gardasil ®9 in immunocompromised patients, with historical controls. The number of subjects to be enrolled in the study was determined based on the primary immunogenicity objective. Condition or disease Intervention/treatment Phase Human Papilloma Virus Human Immunodeficiency Virus Solid Organ Transplant Biological: nine-valent HPV vaccine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (...) transplantation Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Papilloma Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Neoplasms, Squamous Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Vaccines Immunologic Factors Physiological Effects

2018 Clinical Trials

353. Zaleplon in HIV Patients With Depression

Zaleplon in HIV Patients With Depression Zaleplon in HIV Patients With Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Zaleplon in HIV Patients With Depression The safety and scientific validity (...) to Brief Summary: In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS). Condition or disease Intervention/treatment Phase HIV/AIDS Clinical Depression Drug: Zaleplon Phase 2 Detailed Description: An estimated >50% of HIV positive individuals report insomnia. Insomnia and other sleep

2018 Clinical Trials

354. CCR5-modified CD4+ T Cells for HIV Infection

Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Infection HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases (...) to a reduction in the size of the replication-competent HIV reservoir, as measured by the quantitative virus outgrowth assay (QVOA) that is greater than that resulting from infusion of unmodified CD4+ T cells. A total of 30 participants will be randomized to receive one infusion of 0.5 - 4 x 1010 ex vivo expanded autologous CD4+ T cells that have been either modified by transduction with a zinc finger nuclease designed to cleave CCR5 (arm 1, n=20) or unmodified (arm 2, n=10). All participants will be pre

2018 Clinical Trials

355. Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

follow up is complete. Participants will complete surveys at baseline, after the end of the 3 month intervention, and follow up surveys 6 and 9 months after the baseline survey. Condition or disease Intervention/treatment Phase Human Immunodeficiency Virus Behavioral: HealthMindr Application Behavioral: Waitlist Not Applicable Detailed Description: This study aims to evaluate the use and effectiveness of a smartphone-based messaging platform as a public health strategy for improving participants (...) application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr. Behavioral: Waitlist Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States

2018 Clinical Trials

356. eTest: Real-time, Remote Monitoring System for Home-based HIV Testing Among High-risk Men Who Have Sex With Men

Angeles, CA, and Boston, MA. High-risk MSM who have not tested for HIV in the last year will be recruited from MSM-oriented "hook-up" mobile apps, and assigned to receive either (1) HBST with post-test phone counseling/referral ("eTEST" condition), (2) "standard" HBST without active follow-up, or (3) reminders to get tested for HIV at a local clinic ("control" condition) at three month intervals over the course of 12 months. The investigators will explore the impact of the eTEST system on key outcomes (...) will be recruited from MSM-oriented "hook-up" mobile apps, and assigned to receive either (1) HBST with post-test phone counseling/referral ("eTEST" condition), (2) "standard" HBST without active follow-up, or (3) reminders to get tested for HIV at a local clinic ("control" condition) at three month intervals over the course of 12 months. The investigators will explore the impact of the eTEST system on key outcomes, including rates of HIV testing, receipt of additional HIV prevention services, and PrEP

2018 Clinical Trials

357. Evaluating the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

is to evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults. Condition or disease Intervention/treatment Phase HIV Infections Biological: VRC07-523LS Phase 1 Detailed Description: This study will evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults. Participants will be randomly assigned to one of two groups. Participants in Group (...) limit of normal and creatinine less than or equal to institutional upper limits of normal. Virology Negative HIV-1 and -2 blood test: US volunteers must have a negative US Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA). Negative Hepatitis B surface antigen (HBsAg) Negative anti-Hepatitis C virus (anti-HCV) antibodies, or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive Urine Normal urine: Negative

2018 Clinical Trials

358. Sexual dimorphism in HIV-1 infection. (Abstract)

Sexual dimorphism in HIV-1 infection. Sex-specific differences affecting various aspects of HIV-1 infection have been reported, including differences in susceptibility to infection, course of HIV-1 disease, and establishment of viral reservoirs. Once infected, initial plasma levels of HIV-1 viremia in women are lower compared to men while the rates of progression to AIDS are similar. Factors contributing to these sex differences are poorly understood, and range from anatomical differences (...) and differential expression of sex hormones to differences in immune responses, the microbiome and socio-economic discrepancies, all of which may impact HIV-1 acquisition and disease progression. Ongoing research efforts aiming at controlling HIV-1 disease or reducing viral reservoirs need to take these sex-based differences in HIV-1 pathogenesis into account. In this review, we discuss established knowledge and recent findings on immune pathways leading to sex differences in HIV-1 disease manifestations

2018 Seminars in immunopathology

359. Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30) Full Text available with Trip Pro

Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30) BACKGROUND Regorafenib (RGF) is the drug of choice for treating hepatic carcinoma (HCC), but the drug has drawbacks due to resistance and associated adverse effects. Thus, it becomes crucial to understand the causal 'map' of the resistance conferred by RGF (...) , 30 kDa HIV Tat-interacting protein (TIP30), E-cadherin, N-cadherin, and pAMPK were assessed by Western blot analysis. RGF and MTF were exposed to MHCC97H cell and proliferation was quantified by assay of cell viability. Gene silencing and chromatin immunoprecipitation assay were done to reveal the relationship between TIP30 and HIF-2α. The impact of RGF and MTF together on postoperative recurrence and lung metastasis of hepatocellular carcinoma was investigated using tumor engrafted mice after

2018 Medical science monitor : international medical journal of experimental and clinical research

360. Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men Full Text available with Trip Pro

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men Treatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency (...) of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections.We performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment.We treated 25 HIV-infected men with early sexually acquired HCV

2018 Open forum infectious diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>